Wighteone
Based on 3 publication(s) in Google Scholar
Wighteone (6-Isopentenylgenistein; Erythrinin B) is a prenylated isoflavone that acts as a HSP90/EGFRL858R/T790M inhibitor and antifungal agent. Wighteone reduces the expression level of HSP90, blocks EGF-induced phosphorylation of EGFR, and thereby inhibits the downstream ERK and AKT signaling pathways. Wighteone induces cell cycle redistribution, inhibits proliferation and triggers apoptosis in cancer cells. Wighteone can be isolated from Erythrina suberosa, and can also be induced to synthesize in Lotus japonicus under specific conditions. Wighteone can be used to study HER2-positive breast cancer, leukemia, non-small cell lung cancer with EGFRL858R/T790M mutation, and fungal infections.
For research use only. We do not sell to patients.
- Purity : 98.71%
- CAS No.: 51225-30-0
- Formula: C20H18O5
- Molecular Weight:338.35
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Wighteone
MoreAll EGFR Isoforms
More
Biological Activity
Description
IC50 & Target
|
EGFRL858R/T790M |
HSP90 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HSC-2 | CC50 |
0.12 mM
Compound: 22, wighteone
|
Cytotoxicity against human HSC2 cells
Cytotoxicity against human HSC2 cells
|
[PMID: 11170668] |
| U-937 | IC50 |
28 μM
Compound: 14, erythrinin B
|
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
|
[PMID: 17158054] |
| U-937 | IC50 |
32 μM
Compound: 14, erythrinin B
|
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
|
[PMID: 17158054] |
| U-937 | IC50 |
35 μM
Compound: 14, erythrinin B
|
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
|
[PMID: 17158054] |
In Vitro
Wighteone (8.0 mM; 48 h) inhibits the proliferation of HER2-positive MCF-7 breast cancer cells with an inhibition rate of 29.17%[1]; Wighteone also inhibits the proliferation of Ba/F3 EGFRL858R/T790M cells and H1975 cells, with IC50 values of 1.88 μM and 5.70 μM, respectively[2].
Wighteone (0.5-10.0 mM; 48 h) induces apoptosis in HER2-positive MCF-7 breast cancer cells, with a maximum apoptosis rate of 14.98% observed at the concentration of 10.0 mM[1].
Wighteone (0.5-10.0 mM; 24-48 h) downregulates the expression of HSP90 protein in HER2-positive MCF-7 breast cancer cells in vitro in a dose- and time-dependent manner[1].
Wighteone (2.5-10 μM; 24 h) reduces the clonogenic potential of NCI-H1975 cells in a dose-dependent manner[2].
Wighteone (2.5-10 μM; 24 h treatment for flow cytometry, 16 h treatment for WB) induces S-phase cell cycle arrest in NCI-H1975 cells by regulating the expression of key cell cycle regulatory proteins CDK2, cyclin A and cyclin E, and inhibits EGF-induced activation of the EGFR signaling pathway, including its downstream molecules Erk and AKT[2].
Wighteone (2.5-10 μM; 24 h treatment for flow cytometry, 16 h treatment for WB) induces apoptosis in NCI-H1975 cells in a dose-dependent manner by activating the caspase-dependent pathway and regulating pro-apoptotic and anti-apoptotic proteins[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HER2-positive MCF-7 breast cancer cells
-
Concentration:0.5 mM, 5.0 mM, 10.0 mM
-
Incubation Time:24 h, 48 h
-
Result:Significantly reduced HSP90 protein expression compared with the control group, with the inhibitory effect enhanced at higher concentrations.
Showed significantly lower HSP90 expression at 48 h than at 24 h in treated cells.
-
Cell Line:NCI-H1975 human NSCLC cells (EGFR L858R/T790M mutant)
-
Concentration:2.5-10 μM (flow cytometry); 2.5-10 μM (Western blot, following 5 min EGF pre-stimulation)
-
Incubation Time:24 h (flow cytometry); 16 h (Western blot, following 5 min EGF pre-stimulation)
-
Result:Dose-dependently increased the proportion of cells in the S phase.
Significantly decreased CDK2 and cyclin A protein levels and increased cyclin E protein levels in a concentration-dependent manner, compared to EGF alone.
-
Cell Line:HER2-positive MCF-7 breast cancer cells
-
Concentration:0.5 mM, 5.0 mM, 10.0 mM
-
Incubation Time:48 h
-
Result:Induced apoptosis in cells after 48 h of treatment, with apoptotic rates of 4.22% (0.5 mM), 6.54% (5.0 mM), and 14.98% (10.0 mM).
Showed a significantly higher apoptotic rate in the 10.0 mM group compared with the control group and the 0.5 mM group.
-
Cell Line:NCI-H1975 human NSCLC cells (EGFR L858R/T790M mutant)
-
Concentration:2.5-10 μM
-
Incubation Time:24 h for flow cytometry; 16 h for Western blot, following 5 min EGF pre-stimulation
-
Result:Dose-dependently increased the rate of apoptotic cells.
Significantly increased protein levels of cleaved-caspase3, cleaved-caspase9, cleaved-PARP1, and Bax, and decreased Bcl-2 protein levels, compared to EGF alone.
Chemical Information
-
CAS No. 51225-30-0
-
Appearance Solid
-
Molecular Weight 338.35
-
Formula C20H18O5
-
Color Off-white to light yellow
-
SMILES
OC1=C(C2=O)C(OC=C2C3=CC=C(C=C3)O)=CC(O)=C1C/C=C(C)/C
-
Synonyms
6-Isopentenylgenistein; Erythrinin B
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
-
-
J Sep Sci
A Monoclonal Antibody-based Lateral Flow Immunochromatographic Assay for Rapid Detection of Derrisisoflavone A in Derris scandens (Roxb.) Benth. [Abstract]2026 May;49(5):e70428. PMID: 42068121
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (295.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (481 KB)
- English - EN (481 KB)
- Français - FR (481 KB)
- Deutsch - DE (481 KB)
- Norwegian - NO (481 KB)
- Español - ES (481 KB)
- Swedish - SV (481 KB)
- Italian - IT (481 KB)
- Korean - KR (481 KB)
- Portuguese - PT (481 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cao ZW, et al. HSP90 expression and its association with wighteone metabolite response in HER2-positive breast cancer cells. Oncol Lett. 2016;11(6):3719-3722. [Content Brief]
[2]. Sun P, et al. Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer. J Cancer. 2021;12(13):3900-3908. Published 2021 May 5. [Content Brief]
[3]. Liu J, et al. Genistein-Specific G6DT Gene for the Inducible Production of Wighteone in Lotus japonicus. Plant Cell Physiol. 2018;59(1):128-141. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9555 mL | 14.7776 mL | 29.5552 mL | 73.8880 mL |
| 5 mM | 0.5911 mL | 2.9555 mL | 5.9110 mL | 14.7776 mL | |
| 10 mM | 0.2956 mL | 1.4778 mL | 2.9555 mL | 7.3888 mL | |
| 15 mM | 0.1970 mL | 0.9852 mL | 1.9703 mL | 4.9259 mL | |
| 20 mM | 0.1478 mL | 0.7389 mL | 1.4778 mL | 3.6944 mL | |
| 25 mM | 0.1182 mL | 0.5911 mL | 1.1822 mL | 2.9555 mL | |
| 30 mM | 0.0985 mL | 0.4926 mL | 0.9852 mL | 2.4629 mL | |
| 40 mM | 0.0739 mL | 0.3694 mL | 0.7389 mL | 1.8472 mL | |
| 50 mM | 0.0591 mL | 0.2956 mL | 0.5911 mL | 1.4778 mL | |
| 60 mM | 0.0493 mL | 0.2463 mL | 0.4926 mL | 1.2315 mL | |
| 80 mM | 0.0369 mL | 0.1847 mL | 0.3694 mL | 0.9236 mL | |
| 100 mM | 0.0296 mL | 0.1478 mL | 0.2956 mL | 0.7389 mL |